Infantile-onset ascending hereditary spastic paralysis |
IAHSP; spastic paralysis, infantile onset ascending |
Clinical Trial: Efficacy and Functional Outcomes of Botulinum Toxin A Injections to Hamstrings in Flexed Knee Gait in Cerebral Palsy
This study is not yet open for patient recruitment.
Verified by Shriners Hospitals for Children November 2005
|
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Spastic Diplegic Cerebral Palsy | Drug: Botulinum Toxin A | Phase III |
MedlinePlus related topics: Cerebral Palsy
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study
Official Title: Efficacy and Functional Outcomes of Botulinum Toxin A Injections to Hamstrings in Flexed Knee Gait in Cerebral Palsy: A Double-Blind, Randomized, Placebo-Controlled Trial
Secondary Outcomes: Gross Motor Function Measurement (GMFM); Pediatric Outcomes Data Collection Instrument (PODCI); Gillette Functional Assessment Questionnaire (GFAQ); 6-Minute Walk Test; Goal Attainment Scale (GAS)
Expected Total Enrollment: 250
Study start: March 2006
This study proposes to: (1) to determine if injections of BTX-A to the hamstring muscles result in measurable physiologic (body structure and body function) changes not observed with normal saline injections, in children with spastic diplegic CP who walk with a flexed-knee gait pattern; (2) to assess whether physiologic changes translate into functional (activity and participation) improvements; (3) to evaluate family’s perception of change in function, activity, participation, and quality of life.
This study will demonstrate if BTX-A injected into overactive hamstring muscles of children with spastic cerebral palsy (CP) and a flexed-knee walking pattern has measurable effects across the spectrum of dimensions of disablement of the International Classification of Functioning, Disability, and Health (ICF). It is a multi-center, prospective, randomized, double-blind trial comparing results of injection of BTX- A and placebo saline in controls, into overactive hamstring muscles, using multiple outcomes measures. Temporal-spatial gait parameters, instrumented 3DGA kinematics, passive ROM, spasticity measurement with both Ashworth and Tardieu scales, muscle strength/control, Gross Motor Function Measurement (GMFM), Pediatric Outcomes Data Collection Instrument (PODCI), Gillette Functional Assessment Questionnaire (FAQ), 6-Minute Walk Test, and Goal Attainment Scale (GAS), assessing all ICF domains, will be collected at baseline and at 1 month, 3 months, and 6 months post-injection. Power analysis demonstrates the need to randomize 250 children (125 with BTX-A, 125 with saline), allowing for attrition. Nine participating hospitals will contribute patients.
Eligibility
Inclusion Criteria:
- (1) Spastic cerebral palsy; (2) Bilateral lower extremity involvement; (3) Spasticity present in the hamstrings; (4) Flexed knee gait >15 degrees by observation (OGS); (5) Age between 3 and 18 years old; (6) GMFCS Level I to Level IV; (7) Able to walk a minimum of 4 complete steps without resting with and without braces/shoes a minimum of 3 times; (8) Able to follow simple commands; (9) Cooperative with physicians and therapist; (10) Able to tolerate application of equipment to the skin.
Exclusion Criteria:
- (1) Rhizotomy surgery within the last 1 year; (2) Lower extremity surgical procedures (soft tissue or bony) within the past 1 year; (3) Currently implanted and operating Intrathecal Baclofen Pump (oral baclofen OK); (4) Lower extremity BTX-A injections within the past 6 months; (5) Multilevel BTX-A injections; (6) Gait trainer reliance; (7) Serial casting 3 months prior to or during study protocol.
Location and Contact Information
Louisiana
Shiners Hosptials for Children in Shreveport, Shreveport, Louisiana, 71103, United States
Sarah P. Rogers, MPH 859-266-2101 Ext. 1213 srogers@shrinenet.org
Chester Tylkowski, MD, Principal Investigator
Kathleen Montpetit, OT, Principal Investigator
James O. Sanders, MD, Principal Investigator
Diane E. Nicholson, PhD, PT, Principal Investigator
Norman Otsuka, MSc, MD, FACS, Principal Investigator
Ed Quigley, PhD, Principal Investigator
Mark Abel, MD, Principal Investigator
Brad A. Racette, MD, Principal Investigator
Philip E. Gates, MD, Principal Investigator, Shriners Hospitals for Children
More Information
Last Updated: December 8, 2005
Record first received: November 30, 2005
ClinicalTrials.gov Identifier: NCT00261131
Health Authority: United States: Institutional Review Board
ClinicalTrials.gov processed this record on 2006-01-10

Not Signed In -


